• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S ADR (NQ: GMAB )

    27.39 +0.05 (+0.18%)
    Streaming Delayed Price Updated: 12:21 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 125,412
    Open 27.42
    Bid (Size) 27.38 (1)
    Ask (Size) 27.40 (2)
    Prev. Close 27.34
    Today's Range 27.35 - 27.63
    52wk Range 24.53 - 39.53
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. 
    Via Chartmill
    Decoding 10 Analyst Evaluations For Genmab
    Via Benzinga

    Performance

    YTD
    -14.70%
    -14.70%
    1 Month
    -3.49%
    -3.49%
    3 Month
    -2.21%
    -2.21%
    6 Month
    -6.84%
    -6.84%
    1 Year
    -28.43%
    -28.43%

    More News

    Read More
    TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Genmab Announces Changes to its Executive Committee
    From Genmab A/S
    Via Business Wire
    Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
    Via Chartmill
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
    Via Benzinga
    GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
    Via Benzinga
    Exposures COVID-19
    While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
    Via Chartmill
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    Via Chartmill
    NASDAQ:GMAB, an undervalued stock with good fundamentals.
    Via Chartmill
    10 Analysts Assess Genmab: What You Need To Know
    Via Benzinga
    Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
    Via Benzinga
    Exposures Product Safety
    EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    From Genmab A/S
    Via Business Wire
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
    Via Chartmill
    7 Stocks That Could Safely 10X by 2030
    Via InvestorPlace
    Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    From Genmab A/S
    Via Business Wire
    Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
    From Genmab A/S
    Via Business Wire
    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
    From Genmab A/S
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.